Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan;12(1):e220192.
doi: 10.2217/cer-2022-0192. Epub 2022 Dec 14.

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

Ian N Bruce  1 , Sarowar Golam  2 , Jason Steenkamp  3 , Pearl Wang  3 , Evelyn Worthington  3 , Barnabas Desta  4 , Konstantina Psachoulia  5 , Wilma Erhardt  2 , Raj Tummala  5
Affiliations
Comment

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

Ian N Bruce et al. J Comp Eff Res. 2023 Jan.
No abstract available

Keywords: comparative effectiveness research; indirect treatment comparison; randomized controlled trials; simulated treatment comparison; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Comment on

References

    1. Bruce IN, Golam S, Steenkamp J et al. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J. Comp. Eff. Res. 11(10), 765–777 (2022). - PubMed
    1. Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, Phase III trial. Lancet Rheumatol. 1(4), e208–e219 (2019). - PubMed
    1. Morand EF, Furie R, Tanaka Y et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382(3), 211–221 (2020). - PubMed
    1. Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. (Munch.) 63(12), 3918–3930 (2011). - PMC - PubMed
    1. Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase III trial. Lancet 377(9767), 721–731 (2011). - PubMed